287 related articles for article (PubMed ID: 20194742)
1. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
Liu CC; Prior J; Piwnica-Worms D; Bu G
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5136-41. PubMed ID: 20194742
[TBL] [Abstract][Full Text] [Related]
2. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.
Zhang J; Li Y; Liu Q; Lu W; Bu G
Oncogene; 2010 Jan; 29(4):539-49. PubMed ID: 19881541
[TBL] [Abstract][Full Text] [Related]
3. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
Lu W; Liu CC; Thottassery JV; Bu G; Li Y
Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
Ettenberg SA; Charlat O; Daley MP; Liu S; Vincent KJ; Stuart DD; Schuller AG; Yuan J; Ospina B; Green J; Yu Q; Walsh R; Li S; Schmitz R; Heine H; Bilic S; Ostrom L; Mosher R; Hartlepp KF; Zhu Z; Fawell S; Yao YM; Stover D; Finan PM; Porter JA; Sellers WR; Klagge IM; Cong F
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15473-8. PubMed ID: 20713706
[TBL] [Abstract][Full Text] [Related]
5. Modulation of LRP6-mediated Wnt signaling by molecular chaperone Mesd.
Li Y; Lu W; He X; Bu G
FEBS Lett; 2006 Oct; 580(22):5423-8. PubMed ID: 16989816
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer.
Zhu H; Su Z; Ning J; Zhou L; Tan L; Sayed S; Song J; Wang Z; Li H; Sun Q; Liu S; Sha O; Leng F; Chen X; Lu D
Cell Death Dis; 2021 Oct; 12(10):912. PubMed ID: 34615853
[TBL] [Abstract][Full Text] [Related]
7. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.
Lin C; Lu W; Zhang W; Londoño-Joshi AI; Buchsbaum DJ; Bu G; Li Y
PLoS One; 2013; 8(2):e58102. PubMed ID: 23469146
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6.
Červenka I; Wolf J; Mašek J; Krejci P; Wilcox WR; Kozubík A; Schulte G; Gutkind JS; Bryja V
Mol Cell Biol; 2011 Jan; 31(1):179-89. PubMed ID: 20974802
[TBL] [Abstract][Full Text] [Related]
9. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
Wang H; He L; Ma F; Regan MM; Balk SP; Richardson AL; Yuan X
J Biol Chem; 2013 Mar; 288(9):6478-87. PubMed ID: 23306204
[TBL] [Abstract][Full Text] [Related]
10. Role of Wnt Co-Receptor LRP6 in Triple Negative Breast Cancer Cell Migration and Invasion.
Ma J; Lu W; Chen D; Xu B; Li Y
J Cell Biochem; 2017 Sep; 118(9):2968-2976. PubMed ID: 28247948
[TBL] [Abstract][Full Text] [Related]
11. Cooperative folding and ligand-binding properties of LRP6 beta-propeller domains.
Liu CC; Pearson C; Bu G
J Biol Chem; 2009 May; 284(22):15299-307. PubMed ID: 19339249
[TBL] [Abstract][Full Text] [Related]
12. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
Lu W; Lin C; King TD; Chen H; Reynolds RC; Li Y
Cell Signal; 2012 Dec; 24(12):2291-6. PubMed ID: 22820499
[TBL] [Abstract][Full Text] [Related]
13. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.
Lin C; Lu W; Zhai L; Bethea T; Berry K; Qu Z; Waud WR; Li Y
FEBS Lett; 2011 Oct; 585(19):3120-5. PubMed ID: 21907199
[TBL] [Abstract][Full Text] [Related]
14. CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex.
Zhou L; Wang Z; Yu S; Xiong Y; Fan J; Lyu Y; Su Z; Song J; Liu S; Sun Q; Lu D
J Pharmacol Exp Ther; 2020 Apr; 373(1):149-159. PubMed ID: 32015160
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel inhibitor of the canonical Wnt pathway.
Park K; Lee K; Zhang B; Zhou T; He X; Gao G; Murray AR; Ma JX
Mol Cell Biol; 2011 Jul; 31(14):3038-51. PubMed ID: 21576363
[TBL] [Abstract][Full Text] [Related]
16. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
Lu W; Li Y
J Cell Biochem; 2014 Oct; 115(10):1799-807. PubMed ID: 24905570
[TBL] [Abstract][Full Text] [Related]
17. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies.
Gong Y; Bourhis E; Chiu C; Stawicki S; DeAlmeida VI; Liu BY; Phamluong K; Cao TC; Carano RA; Ernst JA; Solloway M; Rubinfeld B; Hannoush RN; Wu Y; Polakis P; Costa M
PLoS One; 2010 Sep; 5(9):e12682. PubMed ID: 20856934
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
[TBL] [Abstract][Full Text] [Related]
19. Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation.
Tanneberger K; Pfister AS; Brauburger K; Schneikert J; Hadjihannas MV; Kriz V; Schulte G; Bryja V; Behrens J
EMBO J; 2011 Apr; 30(8):1433-43. PubMed ID: 21304492
[TBL] [Abstract][Full Text] [Related]
20. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
Benhaj K; Akcali KC; Ozturk M
Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
